11 results about "Cytotoxicity test" patented technology

This invention discloses a method and system for cell viability detection using dual-channel differential dynamic adhesion impedance analysis. The system utilizes a microfluidic chip integrating detection and reference channels to synchronously apply fluid disturbances to both channels, inducing a dynamic process of "adhesion → detachment → re-adhesion" in cells. During this process, the differential impedance curve (after background subtraction) is acquired in real time, and six dynamic feature parameters, including the amplitude and rate of decrease and recovery, are extracted. A ridge regression algorithm is used to construct a cell viability prediction model, and the six dynamic feature parameters are input into the model to obtain cell viability values. This invention effectively eliminates environmental and fluid common-mode noise through differential structure and achieves label-free, in-situ, highly sensitive measurement of cell viability using impedance analysis. It has advantages such as accurate results, good stability, and high automation, and is suitable for fields such as cytotoxicity testing and drug screening.

The invention discloses application of neochlorogenic acid in preparation of a medicine for preventing and / or treating hand-foot-and-mouth disease caused by A16 type coxsackie virus (CVA16) infection, and belongs to the technical field of biological medicine. Researches prove that the neochlorogenic acid has the effect of resisting CVA16 infection on HEK293T cells and H4 cells, after the two cells treated by the neochlorogenic acid are infected by the CVA16, the viral genome RNA abundance is obviously reduced, and the cell lesion death condition is obviously relieved; meanwhile, a cytotoxicity test shows that the neochlorogenic acid has no obvious cytotoxicity to HEK293T cells and only has weak cytotoxicity to H4 cells. Therefore, in a reasonable dosage range, the neochlorogenic acid, which is a low-toxicity natural small molecule compound, can be used for preparing the anti-CVA16 medicine for preventing and / or treating the hand-foot-and-mouth disease caused by CVA16 infection.

The invention provides low-toxicity and low-sensitization fluororubber watchband glue as well as a preparation method and application thereof, and belongs to the technical field of rubber materials. According to the technical scheme of the invention, the raw fluororubber is polymerized by adopting the surfactant containing no fluorine element, and meanwhile, the reinforcing filler system is optimized, so that the skin sensitization and stimulation risks are remarkably reduced. The fluororubber watchband adhesive prepared by the preparation method disclosed by the invention shows excellent biological safety in a cytotoxicity test. The invention provides a novel environment-friendly material solution with safety and reliability for the field of wearable equipment, particularly watchband products in long-term contact with human skin, and has definite market application prospect and popularization value.

The application provides a melt-blown non-woven fabric and a preparation method and application thereof. The first aspect of the application provides a preparation method of a melt-blown non-woven fabric, wherein polypropylene resin is used as a base, nano-silver wires and an electret are added, and then melt extrusion, melt-blown spinning and electret treatment are sequentially performed to obtain an electret melt-blown non-woven fabric; and the electret melt-blown non-woven fabric is subjected to subsequent treatment to obtain a melt-blown non-woven fabric. The melt-blown non-woven fabric provided by the application has good antiviral effect, and the results of multiple complete skin irritation tests show that the skin irritation index of the non-woven fabric is 0, and the skin irritation intensity is non-irritating; in-vitro cytotoxicity test detection shows that the non-woven fabric has no cytotoxicity. Therefore, the melt-blown non-woven fabric provided by the application can be applied to the fields of clothing, medical treatment, industry and the like, and can be particularly applied to the preparation of protective products.

The invention discloses a smoke particulate matter trapping method and a tobacco product in-vitro cytotoxicity testing method, and belongs to the technical field of smoke toxicity analysis. The smoke particulate matter trapping method comprises the following steps: collecting an atomized product generated by smoking a smoke product by adopting a filter disc to form a trapped filter disc; the number of suction ports corresponding to each filter disc is 200 to 400; and carrying out extrusion treatment on the captured filter disc to form a treatment mother solution containing flue gas particulate matters. According to the method, the flue gas particulate matters are collected by adopting the filter disc in a supersaturation manner, the treated mother liquor containing the flue gas particulate matters with high concentration can be obtained through extrusion treatment, and the flue gas particulate matter components of the treated mother liquor are basically consistent with those of the flue gas particulate matters captured by a traditional Cambridge filter disc method; the preparation of the high-concentration smoke particulate matter working solution can be realized, the in-vitro cytotoxicity of tobacco products can be effectively evaluated, and the IC50 value can be obtained.

This invention discloses the application of dermal ethylsin in the preparation of antibacterial and repairing cosmetics or pharmaceuticals, and compositions containing it. Dermal ethylsin can inhibit Propionibacterium acnes, Staphylococcus aureus, and / or Staphylococcus epidermidis, and can promote keratinocyte migration and / or upregulate the expression of repair-related genes. Cytotoxicity tests show that dermal ethylsin has good safety. Human efficacy evaluation shows that serums containing dermal ethylsin can significantly reduce inflammatory papules, improve skin redness, and improve barrier function. Therefore, dermal ethylsin can be used as a dual-action antibacterial and repairing active agent in cosmetics or pharmaceuticals for acne skin care, sensitive skin repair, and / or post-medical aesthetic repair. Dermal ethylsin is derived from *Gnaphalium affine*, has good safety, and is non-irritating to the skin.

The invention discloses an eucalyptol type sesquiterpene lactone TBA and TBB nitrogen mustard derivative as well as a preparation method and application thereof. The structural formulas of the eucalyptol type sesquiterpene lactone TBA and TBB nitrogen mustard derivative are respectively shown as a formula TBA-DJ-1-3 and a formula TBB-DJ-1-3. Cytotoxicity tests show that the nitrogen mustard derivatives can inhibit the proliferation activity of liver cancer cells, particularly, the proliferation inhibition effect of the compound TBA-DJ-2 on HepG2 cancer cells is remarkably better than that of a parent body, and the nitrogen mustard derivatives can be used for clinically preparing anti-liver cancer drugs.

The invention provides an acylhydrazone-Mn complex as well as a preparation method and application thereof. The structural formula of the acylhydrazone-Mn complex is shown in the specification, or in the structural formula, R is a substituent group. According to the invention, 4-diphenylaminobenzoylhydrazone reacts with MnCl2, the acylhydrazone-Mn complex is obtained by utilizing easy formation, strong coordination ability, diverse applications and biological activity of acylhydrazone compounds and utilizing N, O atoms and a plurality of metal ions to form complexes with different structures and properties, and some complexes have the characteristics of anti-tumor and antibacterial activity. A cytotoxicity test, an in-vitro proliferation inhibition activity experiment and an antibacterial experiment show that the synthesized Mn complex not only has a relatively good inhibition effect on tumor cells, but also has relatively low toxicity on normal cells; in addition, the proliferation of P.micro can be effectively inhibited.

The application discloses a wear-resistant vortex spinning core-spun yarn and a preparation method thereof. The core-spun yarn comprises a core yarn and a wrapping yarn, the mass of the core yarn is 30-50% of the mass of the wrapping yarn; the core yarn is zinc-modified cotton yarn obtained through vortex spinning of zinc-modified cotton fibers; and the wrapping yarn is an antibacterial wear-resistant agent modified cotton yarn obtained through vortex spinning of the antibacterial wear-resistant agent modified cotton fibers. The zinc-modified cotton yarn is used as the core yarn, the antibacterial wear-resistant agent modified cotton yarn is used as the wrapping yarn, and the wear-resistant vortex spinning core-spun yarn is prepared through vortex spinning, so that the wear resistance and the antibacterial property of the core-spun yarn product are ensured due to the stable combination of zinc and the antibacterial wear-resistant agent. The cytotoxicity test result also shows that the core-spun yarn product of the application does not obviously produce toxicity to organisms.

The application discloses a kind of detection tyrosinase dual-channel near-infrared ratio fluorescent probe and its preparation method and purposes, wherein the structure of detection tyrosinase dual-channel near-infrared ratio fluorescent probe is as follows: the dual-channel near-infrared ratio fluorescent probe LZD of the application shows good selectivity and sensitive dual-channel fluorescence signal to tyrosinase.Cytotoxicity test shows that the ratio probe has good biocompatibility, and confocal fluorescence microscopic imaging experiment shows that the ratio probe has good light stability to HepG2 cells, can respond to tyrosinase through dual-channel fluorescence, and can carry out confocal fluorescence imaging to extracellular and endogenous tyrosinase of cell.

The invention relates to the field of medicines, and discloses application of cordycepin to preparation of a medicine for treating babesia infection and a pharmaceutical composition of the cordycepin. The invention relates to application of cordycepin in preparation of a medicine for treating babesia infection. The composition contains a therapeutically effective amount of cordycepin and pharmaceutically acceptable carriers or auxiliary materials, can be prepared into dosage forms such as tablets, granules, capsules, oral liquid, injections or suspensions, and is suitable for administration modes such as oral administration. In-vitro evaluation shows that the cordycepin has inhibitory activity on Babesia bovis and Babesia gibsoni, and the median inhibitory concentrations (Ic50) of the cordycepin and the Babesia gibsoni are respectively about 303.8 Nm and 147.5 Nm; in a mouse babesia vole infection model, the parasitic rate peak value can be obviously reduced and delayed through oral administration of 20 Mg / Kg (the model group is about 17.5% / 13th day, and the cordycepin group is about 1.8% / 17th day). A cytotoxicity test (Hff-1, Cck-8) shows that the inhibition rate on cell proliferation under the condition of 100 microns is less than 10%. The cordycepin and the pharmaceutical composition thereof can be used for preventing and / or treating babesia infection.